← SynDRA
FINERENONE
SynDRA canonical compound SYN0034195 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | NR3C2 |
|---|
| Mechanism of action | mineralocorticoid receptor antagonist |
|---|
| Indication | chronic kidney disease (ckd) |
|---|
| Disease area | nephrology |
|---|
All known targets
Mechanisms of action (all sources)
- NR3C2 ANTAGONIST
- Mineralocorticoid receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Drug classes
- Mineralocorticoid Receptor Antagonists
- Nonsteroidal Mineralocorticoid-Receptor Antagonist
ATC classes
- C03D · ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS
Cross-references
Synonyms
- KERENDIA
- Kerendia
- kerendia
- BAY 94-8862
- Finerenona
- Bay94-8862
- BAY-94-8862
- UNII-DE2O63YV8R
- BAY94-8862
- DE2O63YV8R
- Finerenone [USAN:INN]
- Finerenone (JAN/USAN/INN)
- SCHEMBL8157011
- GTPL8678
- DTXSID10146928
- J3.584.878I
- D10633
- (4S)-4-(4-cyano-2-metho
- finerenona
- finerenonum
- RefChem:57201
- DTXCID5069419
- Finerenone (BAY 94-8862)
- Finerenone?
- Kerendia (TN)
- Finerenone (Standard)
- FINERENONE [INN]
- FINERENONE [JAN]
- FINERENONE [USAN]
- FINERENONE [WHO-DD]
- orb1306378
- FINERENONE [ORANGE BOOK]
- SCHEMBL29623206
- SCHEMBL30978927
- WLZ3553
- GLXC-15655
- EX-A2845
- MFCD29047135
Reported adverse events
- Hypotension
- Angioedema
- Hypersensitivity
- Rash
- Urticaria
Look up FINERENONE in the interactive SynDRA portal →